Oslo, Norway, 12 November 2021

Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for
the third quarter 2021 on Thursday, 18 November 2021.

A presentation by Nordic Nanovector's senior management team will be held in
-person and webcast live beginning at 8:30am CET.

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Bjørvika

The webcast can be accessed from
www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=ht
t
p%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrava.c
o
m%7Ca91a12b7fd1942b911c508d9639fcaf4%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%
7
C637650361008651083%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIi
L
CJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=hcy6kYrhFeRtQTxJ%2BodFi%2Fw%2BMHp8W%2
F
4umTDtDdJYsAg%3D&reserved=0) in the section: Investors & Media and a recording
will also be available on this page after the event.

The results report and the presentation will be available at
www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=ht
t
p%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrava.c
o
m%7Ca91a12b7fd1942b911c508d9639fcaf4%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%
7
C637650361008661079%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIi
L
CJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=YpIUKimx78JX14KG4Tcg6D3vx2RnTkqhO2n06
S
0%2B8ag%3D&reserved=0) in the section: Investors & Media/Reports and
Presentation/Interim Reports/2021 from 7:00am CET the same day.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 203 926 8535
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found
at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7Ca91a12b7fd1942b911c508d9639fcaf4%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637650361008661079%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=YpIUKimx78JX14KG4Tcg6D3vx2RnTkqhO2
n
06S0%2B8ag%3D&reserved=0).

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.